Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Documenti analoghi

• One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
  di: Hirotaka Watada
  Pubblicazione: (2024)
• Commentary on “Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes ( post hoc analysis of RECAP study)”
  di: Yu Zhang, et al.
  Pubblicazione: (2025)
• A 90 g/day low‐carbohydrate diet improved glycemic control without decreasing frailty in older patients with type 2 diabetes: A secondary analysis of a randomized controlled trial
  di: Yu‐Ting Wang, et al.
  Pubblicazione: (2025)
• Response to the comment of Wasti on “Association between severity of diabetic complications and risk of cancer in middle‐aged patients with type 2 diabetes”
  di: Yao‐Hsien Tseng, et al.
  Pubblicazione: (2025)
• Association between malnutrition and adverse renal outcomes in patients with type 2 diabetes
  di: Momoko Fujiwara, et al.
  Pubblicazione: (2024)